Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

WHO:

Iterum Therapeutics plc (NASDAQ:ITRM) is focused on delivering

differentiated anti-infectives aimed at combatting the global crisis of multi-drug

resistant pathogens to significantly improve the lives of people affected by

serious and life-threatening diseases around the world.

WHAT:

Conference call to discuss U.S. Food and Drug Administration (FDA) approval of

Iterum's ORLYNVAH™ (Oral Sulopenem) for the treatment of uncomplicated

urinary tract infections (uUTIs).



Speakers include: Corey Fishman (CEO) and Steve Aronin (Senior Vice

President and Head of Clinical Development

WHY:

ORLYNVAH™ (sulopenem etzadroxil and probenecid) is the first oral penem

approved for use in the U.S. and the first FDA-approved product for Iterum.

ORLYNVAH™ is approved for the treatment of uUTIs caused by the designated

microorganisms Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in

adult women who have limited or no alternative oral antibacterial treatment

options. It is only the second FDA-approved treatment for uUTIs in the past two

decades.



For more details, view the press release issued Friday here.

WHEN: 

Monday, October 28, 2024

8:30 a.m. Eastern Daylight Time

Dial-in information:

United States: +1 833-470-1428 | International: +1 404-975-4839

Access code: 936149 

The conference call replay will be available in the Events & Presentations page of Iterum's website following the call.